T2* Magnetic Resonance: Iron and Gold††Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.

JACC: Cardiovascular Imaging

Volumn 1, Issue 5, 2008, Pages 579-581

  Pennell, Dudley J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

heart; heart failure; iron; magnetic resonance; T2*; thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON; IRON CHELATING AGENT;

BLOOD TRANSFUSION; CALIBRATION; CLINICAL TRIAL; COMPUTER PROGRAM; EDITORIAL; HEART FAILURE; HEART HEMOSIDEROSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER HEMOSIDEROSIS; MYOCARDITIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REPRODUCIBILITY; SURVIVAL RATE; THALASSEMIA; CHEMICALLY INDUCED DISORDER; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; HEART DISEASE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART STROKE VOLUME; METABOLISM; NOTE; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; RISK ASSESSMENT;

ECHOCARDIOGRAPHY, DOPPLER; HEART DISEASES; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; STROKE VOLUME; THALASSEMIA; VENTRICULAR FUNCTION, LEFT;

EID: 51549095949     PISSN: 1936878X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcmg.2008.05.001     Document Type: Editorial

References (19)

1. Boddaert N., Le Quan Sang K.H., Rötig A., et al. Selective iron chelation in Friedreich ataxia. Biological and clinical implications. Blood 110 (2007) 401-408
2. Raman S., Winner M., Tran T., et al. In vivo atherosclerotic plaque characterization using magnetic susceptibility distinguishes symptom-producing plaques. J Am Coll Cardiol Imaging 1 (2008) 49-57
3. Ochiai K., Shimada T., Murakami Y., et al. Hemorrhagic myocardial infarction after coronary reperfusion detected in vivo by magnetic resonance imaging in humans: prevalence and clinical implications. J Cardiovasc Magn Reson 1 (1999) 247-256
4. Westwood M.A., Anderson L.J., Maceira A.M., et al. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. J Magn Reson Imaging 25 (2007) 1147-1151
5. Tanner M.A., Galanello R., Dessi C., et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 10 (2008) 12
6. Anderson L.J., Holden S., Davies B., et al. Cardiovascular T2* (T2 star) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22 (2001) 2171-2179
7. Westwood M., Anderson L.J., Firmin D.N., et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 18 (2003) 33-39
8. Westwood M., Anderson L.J., Firmin D.N., et al. Interscanner reproducibility of cardiovascular magnetic resonance in the early diagnosis of myocardial iron overload. J Magn Reson Imaging 18 (2003) 616-620
9. Westwood M.A., Firmin D.N., Gildo M., et al. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging 21 (2005) 531-538
10. Tanner M.A., He T., Westwood M.A., Firmin D.N., and Pennell D.J. Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica 91 (2006) 1388-1391
11. Wood J.C., Otto-Duessel M., Aguilar M., et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 112 (2005) 535-543
12. Tanner M.A., Porter J.B., Westwood M.A., et al. Myocardial T2* in patients with cardiac failure secondary to iron overload. (abstr). Blood 106 (2005) 406
13. Leonardi B., Margossian R., Colan S.D., and Powell A.J. Relationship of magnetic resonance imaging estimation of myocardial iron to left ventricular systolic and diastolic function in thalassemia. J Am Coll Cardiol Img 1 (2008) 572-578
14. Westwood M.A., Wonke B., Maceira A.M., et al. Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major. J Magn Reson Imaging 22 (2005) 229-233
15. Vogel M., Anderson L.J., Holden S., Deanfield J.E., Pennell D.J., and Walker J.M. Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload. Eur Heart J 24 (2003) 113-119
16. Pennell D.J., Berdoukas V., Karagiorga M., et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107 (2006) 3738-3744
17. Tanner M.A., Galanello R., Dessi C., et al. A randomized, placebo controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115 (2007) 1876-1884
18. Borgna-Pignatti C., Cappellini M.D., De Stefano P., et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 107 (2006) 3733-3737
19. Telfer P., Coen P.G., Christou S., et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 91 (2006) 1187-1192